PTPRC and myelodysplastic syndrome: The NCT03128034 trial aims to evaluate escalating doses of 211At-labeled anti-CD45 mAb BC8 (211At-BC8-B10) followed by allogeneic HCT for high-risk acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndrome (MDS).